当前位置: X-MOL 学术Orphanet J. Rare Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of yoga on exercise capacity in patients with lymphangioleiomyomatosis: a nonrandomized controlled study.
Orphanet Journal of Rare Diseases ( IF 3.4 ) Pub Date : 2020-03-16 , DOI: 10.1186/s13023-020-1344-6
Xiangfeng Li 1 , Wenshuai Xu 2 , Lu Zhang 3 , Yi Zu 4 , Yu Li 5 , Yanli Yang 2 , Ying Xiang 4 , Yun Xiang 4 , Ling Chen 5 , Wei Liu 6 , Lixia Chen 3 , Kai-Feng Xu 2, 7
Affiliation  

To evaluate the effects of yoga on exercise capacity and quality of life in patients with lymphangioleiomyomatosis (LAM), a rare cystic lung disease in women. This was a nonrandomized, controlled study conducted in Beijing, China (August 27, 2017 – April 26, 2018). Twenty-six participants were allocated to the intervention (yoga) group (n = 13) or control group (n = 13). The yoga intervention involved a 24-week program of yoga class training for 90 min once a week and no fewer than 2 at-home sessions per week (at least 15 min per session). The 6-min walking distance (6MWD), lung function, serum vascular endothelial growth factor-D (VEGF-D) levels, quality of life, and symptoms of anxiety and depression were measured at baseline, 12-week and 24-week follow-up. An incremental cardiopulmonary exercise test was conducted at baseline and the 24-week follow-up. Eleven patients completed the yoga training program. The yoga group exhibited improvements in the following outcomes versus those of the control group: 6MWD (+ 55 ± 29 m vs + 18 ± 49 m, P = 0.04), anaerobic threshold (3.4 ± 2.4 ml/min/kg vs 1.6 ± 1.4 ml/min/kg, P = 0.035) and peak work load (11.7 ± 14.6 W vs 0.2 ± 9.1 W, P = 0.027). There was no significant difference in peak oxygen consumption (VO2peak), lung function, VEGF-D level, and quality of life between the yoga and control groups. No adverse effects were found in the yoga group. Yoga is a feasible and safe intervention for pulmonary rehabilitation and potentially improves exercise capacity in patients with LAM. (Clinical trial registration number at www.chictr.org.cn: ChiCTR-OON-1701274)
更新日期:2020-04-22
down
wechat
bug